GLP-1 agonists inhibit ox-LDL uptake in macrophages by activating protein kinase A

Journal of Cardiovascular Pharmacology

Volumn 64, Issue 1, 2014, Pages 47-52

  Dai, Yao ^a,b   Dai, Dongsheng ^c   Wang, Xianwei ^a   Ding, Zufeng ^a   Li, Chunlin ^d   Mehta, Jawahar L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Diabetes and Metabolism   (United States)

^c ANHUI MEDICAL UNIVERSITY   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

CD36; GLP 1; ox LDL; PKA

Indexed keywords

CD36 ANTIGEN; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; LIRAGLUTIDE; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; SCAVENGER RECEPTOR A; GLUCAGON LIKE PEPTIDE 1; LOW DENSITY LIPOPROTEIN;

ANTIGEN EXPRESSION; ARTICLE; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FOAM CELL; HUMAN; HUMAN CELL; MACROPHAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGONISTS; ANALOGS AND DERIVATIVES; ATHEROSCLEROSIS; CELL CULTURE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MONOCYTE; PATHOLOGY;

ANTIGENS, CD36; ATHEROSCLEROSIS; CELLS, CULTURED; CYCLIC AMP-DEPENDENT PROTEIN KINASES; FOAM CELLS; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIPOPROTEINS, LDL; MACROPHAGES; MONOCYTES;

EID: 84904261211     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000087     Document Type: Article

References (23)

1. Lu J, Mitra S, Wang X, et al. Oxidative stress and lectin-like ox-LDLreceptor LOX-1 in atherogenesis and tumorigenesis. Antioxid Redox Signal. 2011;15:2301Y2333
2. Mitra S, Goyal T, Mehta JL. Oxidized LDL, LOX-1 and atherosclerosis. Cardiovasc Drugs Ther. 2011;25:419Y429
3. Tomasini MD, Zablocki K, Petersen LK, et al. Coarse grained molecular dynamics of engineered macromolecules for the inhibition of oxidized low-density lipoprotein uptake by macrophage scavenger receptors. Biomacromolecules. 2013;14:2499Y2509
4. Garber AJ. Long-acting glucagon-like peptide 1 receptor agonists: A review of their efficacy and tolerability. Diabetes Care. 2011;34(suppl 2): S279YS284
5. Ban K, Noyan-Ashraf MH, Hoefer J, et al. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide-1 receptor-dependent and -independent pathways. Circulation. 2008;117:2340Y2350
6. Dai Y, Mercanti F, Dai D, et al. LOX-1, a bridge between GLP-1R and mitochondrial ROS generation in human vascular smooth muscle cells. Biochem Biophys Res Commun. 2013;437:62Y66
7. Hallows KR, Alzamora R, Li H, et al. AMP-activated protein kinase inhibits alkaline pH-and PKA-induced apical vacuolar H+-ATPase accumulation in epididymal clear cells. Am J Physiol Cell Physiol. 2009;296: C672YC681
8. Luo G, Kong X, Lu L, et al. Glucagon-like peptide 1 potentiates glucotoxicity-diminished insulin secretion via stimulation of cAMP-PKA signaling in INS-1E cells and mouse islets. Int J BiochemCell Biol. 2013;45: 483Y490
9. Ma L, Dong F, Denis M, et al. Ht31, a protein kinase A anchoring inhibitor, induces robust cholesterol efflux and reverses macrophage foam cell formation through ATP-binding cassette transporter A1. J Biol Chem. 2011;286:3370Y3378
10. Dai Y, Su W, Ding Z, et al. Regulation of MSR-1 and CD36 in macrophages by LOX-1 mediated through PPAR-g. Biochem Biophys Res Commun. 2013;431:496Y500
11. Nagashima M, Watanabe T, Terasaki M, et al. Native incretins prevent the development of atherosclerotic lesions in apolipoprotein E knockout mice. Diabetologia. 2011;54:2649Y2659
12. Ribeiro RA, Vanzela EC, Oliveira CA, et al. Taurine supplementation: Involvement of cholinergic/phospholipase C and protein kinase A pathways in potentiation of insulin secretion and Ca2+ handling in mouse pancreatic islets. Br J Nutr. 2010;104:1148Y1155
13. Kaplan M, Aviram M, Hayek T. Oxidative stress and macrophage foam cell formation during diabetes mellitus-induced atherogenesis: Role of insulin therapy. Pharmacol Ther. 2012;136:175Y185
14. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3: 153Y165
15. Crucet M, Wüst SJ, Spielmann P, et al. Hypoxia enhances lipid uptake in macrophages: Role of the scavenger receptors Lox1, SRA, and CD36. Atherosclerosis. 2013;229:110Y117
16. Ra-c ME, Safranow K, Poncyljusz W. Molecular basis of human CD36 gene mutations. Mol Med. 2007;13:288Y296
17. Febbraio M, Hajjar DP, Silverstein RL. CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. J Clin Invest. 2001;108:785Y791
18. Roberts W, Magwenzi S, Aburima A, et al. Thrombospondin-1 induces platelet activation through CD36-dependent inhibition of the cAMP/protein kinase A signaling cascade. Blood. 2010;116:4297Y4306
19. Skoglund G, Hussain MA, Holz GG. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. Diabetes. 2000;49: 1156Y1164
20. Gromada J, Dissing S, Rorsman P. Desensitization of glucagon-like peptide 1 receptors in insulin-secreting beta TC3 cells: Role of PKA-independent mechanisms. Br J Pharmacol. 1996;118:769Y775
21. Dong Z, Chai W, Wang W, et al. Protein kinase A mediates glucagonlike peptide 1-induced nitric oxide production and muscle microvascular recruitment. Am J Physiol Endocrinol Metab. 2013;304:E222YE228
22. Wang D, Luo P, Wang Y, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 2013;62:1697Y1708
23. Li N, Li B, Brun T, et al. NADPH oxidase NOX2 defines a new antagonistic role for reactive oxygen species and cAMP/PKA in the regulation of insulin secretion. Diabetes. 2012;61:2842Y2850